Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin.
Antimouse antibody is produced from 40 to 68% of the time after administration of Orthoclone OKT3. In patients treated with OKT3, however, if the concomitant immunosuppression is not decreased, the incidence of the antibody production is reduced to 40%. Similarly, 33% of patients developed antihorse antibody after the initial antithymocyte globulin (ATG) administration. Most of the time, the antibody production is low-titered for both OKT3 and ATG.
Shield
C F
CF
Norman
D J
DJ
Marlett
P
P
Fucello
A J
AJ
Goldstein
G
G
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006084:Graft Rejection; D006736:Horses; D006801:Humans; D051379:Mice; D013045:Species Specificity; D013601:T-Lymphocytes / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D001379:Azathioprine